about
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trialsFirst molecular epidemiology study of Mycobacterium tuberculosis in KiribatiBiological weapons preparedness: the role of physicians.Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.Nucleoside analogues and neuropathy in the era of HAART.Role of TNF block genetic variants in HIV-associated sensory neuropathy in black Southern Africans.A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA.Evaluation of the Cavidi ExaVir Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring.HIV-associated sensory neuropathy: risk factors and genetics.Pharmacological treatment of painful HIV-associated sensory neuropathy.The relationship between body composition and knee structure in patients with human immunodeficiency virus.Choice of valve type and poor ventricular catheter placement: Modifiable factors associated with ventriculoperitoneal shunt failure.Psychological Factors Associated With Painful Versus Non-Painful HIV-Associated Sensory Neuropathy.Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy.Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.Polymorphisms in CAMKK2 may predict sensory neuropathy in African HIV patients.TNF Block Gene Variants Associate With Pain Intensity in Black Southern Africans With HIV-associated Sensory Neuropathy.Measuring and monitoring apoptosis and drug toxicity in HIV patients by ligation-mediated polymerase chain reaction.Ubisol-Aqua: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model.Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients.A report on the effect of commencing enfuvirtide on peripheral neuropathy.HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans.Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk.Analysis of a previously identified "pain-protective" haplotype and individual polymorphisms in the GCH1 gene in Africans with HIV-associated sensory neuropathy: a genetic association study.A polymorphism in IL4 may associate with sensory neuropathy in African HIV patients.Macrophage migration inhibitory factor: a potential biomarker for cardiovascular disease in persons with HIV?Physical activity uptake in patients with HIV: who does how much?Polymorphisms in uncoupling protein genesUCP2andUCP3are not associated with HIV-associated sensory neuropathy in African individualsHIV-associated sensory neuropathy: still a problem in the post-stavudine era?
P50
Q21562140-C0FD8A45-5595-421B-A70D-C7759CE2909EQ28485855-FDCD39DB-EF52-4334-A757-3EBBC63FB35CQ30233407-7721E385-2E81-499B-8CAF-1DC15B2B898EQ33373810-33CB54AB-1493-4D6D-A77A-5D58C780C534Q33874791-868E7F95-9E51-49E9-8187-DEC59F46C456Q35071456-208B31C5-54C8-4F30-8B22-4B6385BD0641Q35079928-D4AA3B94-2FAB-4885-B8BD-9D324A400D35Q36180179-5CEE73A5-F2E7-496B-8351-1AD062DACD2CQ37333664-01A8D746-E73C-426C-9369-AF9D38DDB932Q37988382-D2495AAD-BB1A-44C3-AAC2-8F3BAE6BA97DQ38597412-3FDDAAFF-CD05-4959-B034-45FC5457A897Q39216249-9859D521-3347-43FE-99CB-80BA76B69E80Q40116220-2EFF0BEF-6172-460D-953C-7726FE310B23Q40133910-689E218E-D78E-4FD6-9AF4-0CDD921D5C21Q40217724-3CAEDC3E-CB0B-498E-8CB2-CA72D07D643FQ40650654-D1DFC4AA-950A-4F6E-BD07-2ADFB417BF36Q40826704-A711710E-60D6-40C9-8703-3D8E28A264C0Q41440466-874F7C09-B2C1-4B42-BF0B-36550D84EDF7Q42913804-951CEC1A-AB3E-4C28-AE69-815CA5CC4B49Q43160835-0830728E-1189-4BE0-B12F-81EDF98B43C2Q45372642-5BC2EBE4-124A-4356-8EEE-ACE50A18FA43Q46412958-128B8F1C-AD8D-4099-9692-E21577DC1C03Q46610471-AC3CF03C-6B07-4769-A95E-2A144390E736Q46778337-D01C63E3-F3C6-45E1-96D0-7AD388DC7732Q48682392-B6B6357E-808A-4D07-A00B-D70161175D4BQ48970951-278783A6-38A2-4913-82CD-BB8216C97F86Q51814044-1A95A8FC-8482-4F37-A8EF-49A4E7C60AD2Q53211389-AD56A1CD-6ACD-48F1-9AD4-708AE98D81B8Q60731119-5D1592EB-C2FC-41D0-949D-C702E75DE28BQ60731120-E71FCD6B-47BF-4396-B09E-84F0EA731165
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Catherine L Cherry
@es
Catherine L Cherry
@nl
Catherine L Cherry
@sl
Catherine L. Cherry
@en
type
label
Catherine L Cherry
@es
Catherine L Cherry
@nl
Catherine L Cherry
@sl
Catherine L. Cherry
@en
prefLabel
Catherine L Cherry
@es
Catherine L Cherry
@nl
Catherine L Cherry
@sl
Catherine L. Cherry
@en
P106
P1153
26647998800
P21
P31
P496
0000-0001-9816-5193
P569
2000-01-01T00:00:00Z